OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC Cuts Position in Alphatec Holdings, Inc. (NASDAQ:ATEC)

OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC trimmed its position in Alphatec Holdings, Inc. (NASDAQ:ATEC) by 14.8% during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 197,992 shares of the medical technology company’s stock after selling 34,305 shares during the quarter. OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Alphatec were worth $1,818,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. R Squared Ltd purchased a new position in shares of Alphatec in the 4th quarter valued at $29,000. Comerica Bank raised its position in Alphatec by 66.8% in the fourth quarter. Comerica Bank now owns 3,116 shares of the medical technology company’s stock valued at $29,000 after purchasing an additional 1,248 shares during the period. Nisa Investment Advisors LLC raised its holdings in shares of Alphatec by 973.3% during the 4th quarter. Nisa Investment Advisors LLC now owns 4,669 shares of the medical technology company’s stock valued at $43,000 after buying an additional 4,234 shares during the period. Quarry LP raised its holdings in shares of Alphatec by 79.2% during the 4th quarter. Quarry LP now owns 5,374 shares of the medical technology company’s stock valued at $49,000 after buying an additional 2,375 shares during the period. Finally, Newton One Investments LLC purchased a new stake in shares of Alphatec during the 4th quarter valued at about $50,000. 66.35% of the stock is currently owned by hedge funds and other institutional investors.

Alphatec Stock Up 0.4%

Shares of NASDAQ:ATEC opened at $12.72 on Wednesday. The company has a current ratio of 2.32, a quick ratio of 1.15 and a debt-to-equity ratio of 30.21. The company has a fifty day simple moving average of $10.56 and a 200 day simple moving average of $10.23. The firm has a market cap of $1.86 billion, a PE ratio of -9.94 and a beta of 1.06. Alphatec Holdings, Inc. has a 12-month low of $4.88 and a 12-month high of $12.85.

Alphatec (NASDAQ:ATEC) last released its earnings results on Thursday, May 1st. The medical technology company reported ($0.35) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.23). The company had revenue of $169.18 million during the quarter, compared to the consensus estimate of $167.57 million. Alphatec had a negative return on equity of 541.39% and a negative net margin of 31.06%. Alphatec’s revenue for the quarter was up 22.2% on a year-over-year basis. During the same period in the previous year, the firm posted ($0.34) EPS. On average, equities research analysts anticipate that Alphatec Holdings, Inc. will post -1.08 EPS for the current fiscal year.

Insider Activity at Alphatec

In other news, COO Scott Lish sold 12,000 shares of the business’s stock in a transaction that occurred on Monday, May 5th. The stock was sold at an average price of $12.12, for a total value of $145,440.00. Following the completion of the sale, the chief operating officer now directly owns 826,251 shares in the company, valued at approximately $10,014,162.12. The trade was a 1.43% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Patrick Miles sold 32,393 shares of the business’s stock in a transaction on Wednesday, February 26th. The shares were sold at an average price of $10.89, for a total transaction of $352,759.77. Following the sale, the chief executive officer now owns 5,940,391 shares of the company’s stock, valued at approximately $64,690,857.99. The trade was a 0.54% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 126,945 shares of company stock valued at $1,416,352 over the last three months. 20.90% of the stock is owned by insiders.

Analyst Upgrades and Downgrades

ATEC has been the topic of several analyst reports. Piper Sandler reiterated an “overweight” rating and set a $15.00 target price (up from $13.00) on shares of Alphatec in a report on Friday, May 2nd. StockNews.com upgraded shares of Alphatec from a “sell” rating to a “hold” rating in a research note on Friday, February 28th. Needham & Company LLC reaffirmed a “buy” rating and set a $16.00 price target on shares of Alphatec in a research note on Friday, May 2nd. Barclays lifted their price target on shares of Alphatec from $20.00 to $21.00 and gave the stock an “overweight” rating in a research note on Wednesday, January 22nd. Finally, HC Wainwright reaffirmed a “buy” rating and set a $20.00 price target on shares of Alphatec in a research note on Monday, April 14th. Two investment analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $17.89.

Alphatec Company Profile

Alphatec Holdings, Inc, a medical technology company, designs, develops, and advances technologies for the surgical treatment of spinal disorders in the United States and internationally. It manufactures and sells implants and instruments through third-party suppliers. The company offers Alpha InformatiX product platform, including EOS imaging system that provides full-body imaging; VEA alignment mobile application, which leverages EOS technology to more quickly quantify alignment parameters on a mobile device; SafeOp Neural InformatiX System that automates electromyographic and somatosensory evoked potential monitoring; and Valence, an intra-operative system that integrates navigation and robotics into spine procedures, as well as Sigma Prone TransPsoas (PTP) Access and PTP Patient Positioning Systems.